✦ LIBER ✦

PDB36 LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES

✍ Scribed by Gaebler J Aledort; Y Samyshkin; ALG Guillermin; A Lloyd

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB27 COST-EFFECTIVENESS OF EXENATIDE VE

✍ D Bruhn; S Malhan; S Kavuncubasi; J Smith-Palmer; V Reed 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Estimating the Long-Term Cost-Effectiven

✍ Michael E. Minshall; Alan K. Oglesby; Matthew E. Wintle; William J. Valentine; S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

PDB51 COST-EFFECTIVENESS OF EXENATIDE VE

✍ JL Palmer; CG Pinto; R Duarte; L Miguel; Z Gregor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Results of a model analysis of the cost-

✍ Won Chan Lee; Christopher Conner; Mette Hammer 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Evaluating the Long-Term Cost-Effectiven

✍ William J. Valentine; Andrew J. Palmer; Morten Lammert; Jakob Langer; Michael Br 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 505 KB

PDB55 Estimating the Cost-Effectiveness

✍ B. Curtis; R. Pollock; J. Smith-Palmer; W. Valentine 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB